Long Shortz with Island Pharma: Targeting Ebola, Zika & Marburg with Gallidesivir

Tylah Tully chats with Island Pharmaceuticals (ASX:ILA) managing director Dr David Foster after the company expanded its antiviral portfolio with the acquisition of the Galidevsivir program from NASDAQ-listed BioCryst Pharmaceuticals. 

The broad-spectrum drug targets deadly viruses like Ebola, Marburg, and Zika, and Island plans to pursue FDA approval under the “animal rule” pathway -potentially making it just one animal study away from filing a new drug application.

Foster says the next steps involve FDA engagement and preparing for the final efficacy study, setting the stage for a potentially rapid regulatory path.

Watch the video to learn more.

This video was developed in collaboration with Island Pharmaceuticals, a Stockhead client at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.